1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24503
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKopylov, U.en
dc.contributor.authorMantzaris, G. J.en
dc.contributor.authorKatsanos, K. H.en
dc.contributor.authorReenaers, C.en
dc.contributor.authorEllul, P.en
dc.contributor.authorRahier, J. F.en
dc.contributor.authorIsraeli, E.en
dc.contributor.authorLakatos, P. L.en
dc.contributor.authorFiorino, G.en
dc.contributor.authorCesarini, M.en
dc.contributor.authorTsianos, E. V.en
dc.contributor.authorLouis, E.en
dc.contributor.authorBen-Horin, S.en
dc.date.accessioned2015-11-24T19:41:35Z-
dc.date.available2015-11-24T19:41:35Z-
dc.identifier.issn1365-2036-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24503-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntibodies, Monoclonal/*administration & dosageen
dc.subjectCrohn Disease/*drug therapyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectFemaleen
dc.subjectGastrointestinal Agents/*administration & dosageen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectRetrospective Studiesen
dc.subjectStatistics as Topicen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.subjectYoung Adulten
dc.titleThe efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximaben
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1111/j.1365-2036.2010.04523.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21118397-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1365-2036.2010.04523.x/asset/j.1365-2036.2010.04523.x.pdf?v=1&t=h0tasl6y&s=c80a19faa37e1b5b17ceb51ef2f716bfe2942940-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractBACKGROUND: Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks. AIM: We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling. METHODS: This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). RESULTS: Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.). CONCLUSION: In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks.en
heal.journalNameAliment Pharmacol Theren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Kopylov-2011-The efficacy of shor.pdf197.68 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons